Novo Nordisk (NVO) Stock: Plunges 9% After ZEUS Heart Trial Misses Key Goal

TLDR

• Novo Nordisk stock plunges over 9% after ZEUS misses its key heart trial goal.

• ZEUS shows lower inflammation but no reduction in major cardiovascular events.

• Ziltivekimab records a 0.99 hazard ratio against placebo in the phase 3 trial.

• Serious infection rates rise with treatment while overall mortality stays level.

• HERMES and ARTEMIS continue with key trial results expected during early 2027.

Novo Nordisk stock plunged 9.18% to $46.85 after its ZEUS heart trial failed to reduce major cardiovascular events. The setback weakened confidence in ziltivekimab, despite clear biological activity against inflammation linked to cardiovascular disease and kidney damage. However, the result will not change Novo Nordisk’s adjusted operating profit outlook for the full 2026 financial reporting year.

Novo Nordisk A/S, NVO

ZEUS Trial Misses Main Cardiovascular Goal

Novo Nordisk tested ziltivekimab in more than 6,300 people with cardiovascular disease, kidney disease, and persistent systemic inflammation. The phase 3 study compared a monthly 15-milligram dose against placebo under controlled, double-blind trial conditions throughout the study. Researchers measured cardiovascular death, non-fatal heart attacks, and non-fatal strokes as the combined primary trial outcome for efficacy.

… Continue reading the full article at the original source below.